Pricing Log in Create free account
Saturday 17 October 2026 Export CPIX’s income statement to Excel — free account

Cumberland Pharmaceuticals Inc.

CPIX Healthcare Drug Manufacturers Specialty & Generic

In the quarter to June 2026, revenue fell 56.3%, EPS fell 440.0%, free cash flow fell 82.8% and total debt was flat, each against the same quarter a year earlier.

7.18 0.36 −4.77%
Market cap
$113.0M
P/E
0.0×
Fwd P/E
−12.2×
Dividend yield
0.00%
F-score
6/9
Altman Z
0.65
Beneish M
−2.58
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 41.60%

Capital & Financial Ratios $m

Market Cap 112.97
Revenue 41.73
Net Income (10.94)
Free Cash Flow 0.58
Net Debt (3.86)
Current Ratio 0.96 (below 1: weak)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (12.20) (negative: loss-making)
P/S ratio 2.58
P/B ratio 6.29 (above 6: high)
Past 5Y EPS Growth —
This Y EPS Growth —
Next Y EPS Growth —
Next Y revenue growth 24.77% (at or above 10%: strong)
Next 5Y EPS Growth 30.00% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.7×, against a ten-year median of 1.2×; over the ten years it ranged from 0.4× in 2024 to 3.0× in 2019.
P/S against its own 10 years 75.93%
10-year low 10-year high
P/B against its own 10 years 98.64%
10-year low 10-year high
EV/Sales against its own 10 years 95.61%
10-year low 10-year high
EV/FCF against its own 10 years 95.04%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate 0.00
Annual Dividend Yield 0.00%
total individual payouts
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2018 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 18 18 11 4
Receivables 10 12 17 13
Inventory 5 4 6 0
Other — — — —
36 36 37 34
2023 2024 2025 Q'26
Payables 14 14 19 20
ST’ Debt — 5 — —
Other 14 12 18 2
28 32 37 35

Compound Annual Growth %

10y 5y 3y
Sales 2.88% 3.52% 1.95%
Cash Flow (1.74%) (1.85%) (16.44%)
Earnings 0.00% 0.00% 0.00%
Book Value (10.78%) (12.14%) (11.97%)

Revenue $m

Mar Jun Sep Dec Year
’26 9 0 — — —
’25 12 0 8 24 45
’24 8 10 9 10 38
’23 9 11 10 9 40
’22 11 10 11 9 42
’21 11 9 8 8 36
’20 8 10 9 10 37
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 0 0 — — —
’25 4 1 0 0 5
’24 (2) (1) 0 2 (1)
’23 (1) 5 1 1 6
’22 0 2 3 4 8
’21 2 3 0 2 6
’20 1 3 1 1 5
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 0 0 — — —
’25 4 1 0 0 5
’24 (2) (1) 0 2 (1)
’23 (2) 5 1 1 6
’22 0 2 2 2 6
’21 2 3 0 2 6
’20 0 3 0 1 3
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.22) (0.27) — — —
’25 0.08 (0.05) (0.13) (0.09) (0.19)
’24 (0.14) (0.08) (0.11) (0.14) (0.46)
’23 0.01 0.06 (0.07) (0.44) (0.44)
’22 (0.09) (0.09) (0.03) (0.17) (0.38)
’21 0.01 0.08 (0.07) (0.26) (0.24)
’20 (0.07) (0.06) (0.03) (0.06) (0.22)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 4.20 5.28 5.06 4.19 2.77 2.20 1.89 1.43 1.04 1.85

Analyst estimates 2026–2028

Powerpack
High 6.00 7.96 7.45 6.99 5.44 7.51 5.65 2.91 3.05 7.25
People
People Employees 82 84 80 94 90 83 85 91 91 93
Revenue/emp, $m 0.40 0.49 0.37 0.37 0.42 0.43 0.49 0.43 0.42 0.48
Income, $m
Income, $m Revenue 33 41 29 34 37 36 42 40 38 45
Gross margin, % 81.96 82.09 79.50 78.42 76.89 75.51 78.29 84.66 82.61 85.02
EBT (1) (4) (11) (9) (7) (6) (6) (6) (6) (3)
EBT margin, % (4.04) (9.42) (36.82) (27.02) (17.55) (15.46) (13.29) (15.89) (17.08) (6.31)
Net income (1) (8) (7) (4) (3) (4) (6) (6) (6) (3)
Depreciation 2 3 3 4 5 5 5 8 5 4
Per share, $
Per share, $ Revenue 2.03 2.59 1.88 2.23 2.47 2.41 2.88 2.77 2.69 3.00
Earnings (0.06) (0.50) (0.45) (0.23) (0.22) (0.24) (0.38) (0.44) (0.46) (0.19)
Cash flow 0.04 (0.03) 0.20 0.20 0.36 0.43 0.58 0.43 (0.04) 0.33
Capex (0.13) (0.09) (0.27) (0.07) (0.14) (0.02) (0.14) (0.03) (0.01) (0.01)
Free cash flow (0.10) (0.13) (0.07) 0.13 0.22 0.40 0.44 0.39 (0.06) 0.32
Book value 4.50 4.02 3.56 3.32 3.09 2.86 2.47 2.05 1.60 1.65
Shares, m 16 16 16 15 15 15 15 14 14 15
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S 2.88 2.73 3.21 2.31 1.19 1.93 0.80 0.67 0.88 1.33
P/B 1.30 1.76 1.69 1.55 0.95 1.63 0.94 0.90 1.48 2.41
EV/Sales 1.49 1.75 2.66 2.05 0.96 1.63 0.72 0.54 0.81 1.30
EV/FCF (31.45) (35.13) (67.04) 34.60 10.90 9.78 4.74 3.77 (38.68) 12.21
Cash, $m
Cash, $m Operating cash flow 1 (1) 3 3 5 6 8 6 (1) 5
Capex (2) (1) (4) (1) (2) 0 (2) 0 0 0
Free cash flow (2) (2) (1) 2 3 6 6 6 (1) 5
Balance, $m
Balance, $m Working capital 51 51 31 26 24 26 17 8 5 0
Total debt 4 10 20 19 16 16 16 13 15 5
Net debt (46) (40) (16) (9) (9) (11) (3) (6) (3) (6)
Shareholders’ equity 73 64 56 51 47 43 36 29 23 25
Returns, %
Returns, % ROA (1.02) (8.55) (6.76) (3.26) (3.32) (3.88) (6.28) (7.19) (8.24) (3.72)
ROIC (3.31) (10.79) (17.75) (13.73) (10.46) (15.22) (10.94) (25.17) (20.24) (9.51)
ROE (1.26) (11.64) (11.65) (6.63) (6.82) (7.84) (14.18) (19.25) (25.02) (12.05)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Cumberland Pharmaceuticals Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
DERM Journey Medical Corporation $144.7M — (loss-making) 91.8× +23.33% (above 0%: growing) n/m −84.08% (below 0%: shrinking) 66.81% 2.46% Compare
ORGO Organogenesis $142.8M — (loss-making) — (loss-making) −56.68% (below 0%: shrinking) n/m +10.29% (above 0%: growing) 45.90% (116.54%) Compare
CRDL Cardiol Therapeutics Inc. $138.8M — (loss-making) — (loss-making) — n/m +10.61% (above 0%: growing) 0.00% 0.00% Compare
OGI Organigram Global Inc. $131.4M 2.0× 11.4× +49.28% (above 0%: growing) n/m −192.32% (below 0%: shrinking) 39.16% 5.04% Compare
BGM BGM Group Ltd. $114.7M 144× 44.9× −2.59% (below 0%: shrinking) −85.71% (below 0%: shrinking) +3.00% (above 0%: growing) 7.12% 0.00% Compare
PROCF Sofgen Pharma S.A $114.0M 0.1× 4.0× +17.28% (above 0%: growing) n/m +231.11% (above 0%: growing) 56.09% 36.48% Compare
CPIX Cumberland Pharmaceuticals Inc. $113.0M — (loss-making) — (loss-making) −56.28% (below 0%: shrinking) n/m −82.78% (below 0%: shrinking) 100.00% (1,898.20%)
CLVR Clever Leaves Holdings Inc. $96.5M — (loss-making) — (loss-making) +5.36% (above 0%: growing) n/m +70.31% (above 0%: growing) (7.46%) (105.91%) Compare
CTOR Citius Oncology, Inc. $69.4M — (loss-making) — — n/m 0.00% 67.07% (583.53%) Compare
Median of peers $123.0M 2.0× 28.2× +11.32% — +6.65% 42.53% 0.00%

All 86 Drug Manufacturers Specialty & Generic stocks →

Cumberland Pharmaceuticals Inc. (CPIX) key facts

  • Cumberland Pharmaceuticals Inc. (CPIX) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, CPIX traded at $7.18, a market capitalization of $113.0 million.
  • Return on equity was −12.1% and debt-to-equity 0.00.
  • Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 0.65 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Cumberland Pharmaceuticals Inc. (CPIX) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/CPIX · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com